Valeria Cinquina1, Claudia Ciaccio2, Marina Venturini3, Riccardo Masson2, Marco Ritelli1, Marina Colombi1. 1. Division of Biology and Genetics, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy. 2. Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. 3. Division of Dermatology, Department of Clinical and Experimental Sciences, Spedali Civili University Hospital Brescia, Brescia, Italy.
Abstract
BACKGROUND: PURA syndrome is rare autosomal dominant condition characterized by moderate to severe neurodevelopmental delay with absence of speech in nearly all patients and lack of independent ambulation in many. Early-onset problems include excessive hiccups, hypotonia, hypersomnolence, hypothermia, feeding difficulties, recurrent apneas, epileptic seizures, and abnormal nonepileptic movements. Other less common manifestations comprise congenital heart defects, urogenital malformations, and various skeletal, ophthalmological, gastrointestinal, and endocrine anomalies. Up to now, 78 individuals with PURA syndrome and 64 different pathogenic variants have been reported, but no clear-cut genotype-phenotype correlations have emerged so far. Herein, we report the clinical and molecular characterization of a 3-year-old girl with severe hypotonia, global developmental delay, and soft, loose skin, who came to our attention with a suspicion of cutis laxa (CL), which denotes another condition with variable neurodevelopmental problems. METHODS: Amplicon-based whole exome sequencing was performed, and an in-house pipeline was used to conduct filtering and prioritization of variants. New prediction algorithms for indels were used to validate the pathogenicity of the PURA variant, and results were confirmed with the Sanger method. Finally, we collected clinical and mutational data of all PURA syndrome patients reported yet and compared the clinical features with those of our patient. RESULTS: Clinical evaluation and biochemical investigations excluded CL and prompted to perform whole exome sequencing, which confirmed the absence of pathogenic variants in all CL-related genes and revealed the known PURA c.697_699del, p.(Phe233del) variant, identified hitherto in seven additional children with PURA syndrome. CONCLUSIONS: Our data expand the phenotypic spectrum of PURA syndrome by showing that it can be regarded as a differential diagnosis for cutis laxa in early infancy. Our patient and literature review emphasize that a wide clinical variability exists not only between individuals with different PURA variants, but also among patients with the same causal mutation.
BACKGROUND:PURA syndrome is rare autosomal dominant condition characterized by moderate to severe neurodevelopmental delay with absence of speech in nearly all patients and lack of independent ambulation in many. Early-onset problems include excessive hiccups, hypotonia, hypersomnolence, hypothermia, feeding difficulties, recurrent apneas, epileptic seizures, and abnormal nonepileptic movements. Other less common manifestations comprise congenital heart defects, urogenital malformations, and various skeletal, ophthalmological, gastrointestinal, and endocrine anomalies. Up to now, 78 individuals with PURA syndrome and 64 different pathogenic variants have been reported, but no clear-cut genotype-phenotype correlations have emerged so far. Herein, we report the clinical and molecular characterization of a 3-year-old girl with severe hypotonia, global developmental delay, and soft, loose skin, who came to our attention with a suspicion of cutis laxa (CL), which denotes another condition with variable neurodevelopmental problems. METHODS: Amplicon-based whole exome sequencing was performed, and an in-house pipeline was used to conduct filtering and prioritization of variants. New prediction algorithms for indels were used to validate the pathogenicity of the PURA variant, and results were confirmed with the Sanger method. Finally, we collected clinical and mutational data of all PURA syndromepatients reported yet and compared the clinical features with those of our patient. RESULTS: Clinical evaluation and biochemical investigations excluded CL and prompted to perform whole exome sequencing, which confirmed the absence of pathogenic variants in all CL-related genes and revealed the known PURAc.697_699del, p.(Phe233del) variant, identified hitherto in seven additional children with PURA syndrome. CONCLUSIONS: Our data expand the phenotypic spectrum of PURA syndrome by showing that it can be regarded as a differential diagnosis for cutis laxa in early infancy. Our patient and literature review emphasize that a wide clinical variability exists not only between individuals with different PURA variants, but also among patients with the same causal mutation.
Authors: Kana Hosoki; Tohru Ohta; Jun Natsume; Sumiko Imai; Akihisa Okumura; Takeshi Matsui; Naoki Harada; Carlos A Bacino; Fernando Scaglia; Jeremy Y Jones; Norio Niikawa; Shinji Saitoh Journal: Am J Med Genet A Date: 2012-06-18 Impact factor: 2.802
Authors: Edward M Johnson; Yayoi Kinoshita; David B Weinreb; Margaret J Wortman; Ruth Simon; Kamel Khalili; Bettina Winckler; Jennifer Gordon Journal: J Neurosci Res Date: 2006-05-01 Impact factor: 4.164
Authors: Ngak-Leng Sim; Prateek Kumar; Jing Hu; Steven Henikoff; Georg Schneider; Pauline C Ng Journal: Nucleic Acids Res Date: 2012-06-11 Impact factor: 16.971
Authors: Margot R F Reijnders; Robert Janowski; Mohsan Alvi; Jay E Self; Ton J van Essen; Maaike Vreeburg; Rob P W Rouhl; Servi J C Stevens; Alexander P A Stegmann; Jolanda Schieving; Rolph Pfundt; Katinke van Dijk; Eric Smeets; Connie T R M Stumpel; Levinus A Bok; Jan Maarten Cobben; Marc Engelen; Sahar Mansour; Margo Whiteford; Kate E Chandler; Sofia Douzgou; Nicola S Cooper; Ene-Choo Tan; Roger Foo; Angeline H M Lai; Julia Rankin; Andrew Green; Tuula Lönnqvist; Pirjo Isohanni; Shelley Williams; Ilene Ruhoy; Karen S Carvalho; James J Dowling; Dorit L Lev; Katalin Sterbova; Petra Lassuthova; Jana Neupauerová; Jeff L Waugh; Sotirios Keros; Jill Clayton-Smith; Sarah F Smithson; Han G Brunner; Ceciel van Hoeckel; Mel Anderson; Virginia E Clowes; Victoria Mok Siu; The Ddd Study; Paulo Selber; Richard J Leventer; Christoffer Nellaker; Dierk Niessing; David Hunt; Diana Baralle Journal: J Med Genet Date: 2017-11-02 Impact factor: 6.318
Authors: Kymberleigh A Pagel; Danny Antaki; AoJie Lian; Matthew Mort; David N Cooper; Jonathan Sebat; Lilia M Iakoucheva; Sean D Mooney; Predrag Radivojac Journal: PLoS Comput Biol Date: 2019-06-14 Impact factor: 4.475
Authors: Christopher Douville; David L Masica; Peter D Stenson; David N Cooper; Derek M Gygax; Rick Kim; Michael Ryan; Rachel Karchin Journal: Hum Mutat Date: 2015-10-26 Impact factor: 4.878
Authors: Aleksandra Jezela-Stanek; Elżbieta Ciara; Dorota Jurkiewicz; Marzena Kucharczyk; Maria Jędrzejowska; Krystyna H Chrzanowska; Małgorzata Krajewska-Walasek; Tomasz Żemojtel Journal: Mol Genet Genomic Med Date: 2020-04-26 Impact factor: 2.183